

§ 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The erythromycin estolate used in making the batch for potency, pH, moisture, crystallinity, and identity.

(b) The batch for potency, moisture, and pH.

(ii) Samples required:

(a) The erythromycin estolate used in making the batch: 10 packages, each containing not less than 300 milligrams.

(b) The batch: A minimum of 5 immediate containers.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Reconstitute the sample as directed in the labeling. Withdraw an accurately measured representative volume of the reconstituted suspension and add sufficient methyl alcohol to give a concentration of 2.5 milligrams of erythromycin base per milliliter (estimated). Dilute this entire mixture with sufficient 0.1M potassium phosphate buffer, pH 8 (solution 3), to give a concentration of 1.0 milligram of erythromycin base per milliliter (estimated). Hydrolyze in a 60° C. constant temperature water bath for 2 hours or at room temperature for 16 to 18 hours. Further dilute with solution 3 to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *Moisture*. Proceed as directed in § 436.201 of this chapter.

(3) *pH*. Proceed as directed in § 436.202(b) of this chapter, using the suspension prepared as directed in the labeling.

[39 FR 19149, May 30, 1974, as amended at 50 FR 19921, May 13, 1985]

§ 452.115f Erythromycin estolate chewable tablets.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Erythromycin estolate chewable tablets are tablets composed of erythromycin estolate and suitable and harmless diluents, binders, buffers, colorings, and flavorings. Each tablet contains erythromycin estolate equivalent to either 125 or 250 milligrams of erythromycin. Its potency is satisfactory if it is not less than 90 percent and

not more than 115 percent of the number of milligrams of erythromycin that it is represented to contain. The moisture content is not more than 4 percent. The erythromycin estolate used in making the batch conforms to the standards prescribed by § 452.15(a)(1).

(2) *Labeling*. It shall be labeled in accordance with § 432.5 of this chapter.

(3) *Requests for certification; samples*. In addition to the requirements of § 431.1 of this chapter, each such request shall contain:

(i) Results of tests and assays on:

(a) The erythromycin estolate used in making the batch for potency, moisture, pH, crystallinity, and identity.

(b) The batch for potency and moisture.

(ii) Samples required:

(a) The erythromycin estolate used in making the batch: 10 packages, each consisting of not less than 300 milligrams.

(b) The batch: A minimum of 30 tablets.

(b) *Tests and methods of assay*—(1) *Potency*. Proceed as directed in § 436.105 of this chapter, preparing the sample for assay as follows: Blend a representative number of tablets in a high-speed glass blender for 2 to 3 minutes in 200 milliliters of methyl alcohol. Add 300 milliliters of 0.1M potassium phosphate buffer, pH 8.0 (solution 3), and blend again for 2 to 3 minutes. Hydrolyze this solution in a 60° C. constant temperature water bath for 2 hours or at room temperature for 16 to 18 hours. Further dilute with solution 3 to the reference concentration of 1.0 microgram of erythromycin base per milliliter (estimated).

(2) *Moisture*. Proceed as directed in § 436.201 of this chapter.

[39 FR 19149, May 30, 1974, as amended at 50 FR 19921, May 13, 1985]

§ 452.115g Erythromycin estolate and sulfisoxazole acetyl oral suspension.

(a) *Requirements for certification*—(1) *Standards of identity, strength, quality, and purity*. Erythromycin estolate and sulfisoxazole acetyl oral suspension is erythromycin estolate and sulfisoxazole acetyl with suitable and harmless buffer substances, preservatives, solvents, stabilizers, emulsifiers, dispersing agents, colorings, and